ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Aortic Dilation Growth Patterns Reshape Surveillance 11/05/25"
Episode Synopsis
Welcome to Cardiology Today – Recorded November 05, 2025. This episode summarizes 5 key cardiology studies on topics like gender-affirming hormone therapy and United States. Key takeaway: Aortic Dilation Growth Patterns Reshape Surveillance.
Article Links:
Article 1: Transgender persons receiving gender-affirming hormone therapy: risk of acute cardiovascular events in a Dutch cohort study. (European heart journal)
Article 2: Finerenone in patients with severe heart failure: The FINEARTS-HF trial. (European journal of heart failure)
Article 3: Short- and mid-term effects of empagliflozin on sodium balance and fluid regulation in chronic heart failure. (European journal of heart failure)
Article 4: Sex Disparities in Ischemic Heart Disease Mortality Across United States: The Southern Burden of Excess Body Weight and Diet. (Journal of the American Heart Association)
Article 5: Growth Trajectories in Ascending Thoracic Aortic Dilation: Classification and Implications for the Effectiveness of Real-World Imaging Surveillance. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/aortic-dilation-growth-patterns-reshape-surveillance-11-05-25/
Featured Articles
Article 1: Transgender persons receiving gender-affirming hormone therapy: risk of acute cardiovascular events in a Dutch cohort study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41187090
Summary: This study investigated the association between gender-affirming hormone therapy and cardiovascular event risk in transgender individuals compared to the general population. A key methodological advancement was the adjustment for socioeconomic status and lifestyle factors, which were not accounted for in previous research. This Dutch cohort study aims to provide a more accurate assessment of cardiovascular risk in this specific population. The research is critical for refining cardiovascular care guidelines and enhancing risk stratification for transgender persons receiving gender-affirming hormone therapy.
Article 2: Finerenone in patients with severe heart failure: The FINEARTS-HF trial.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41186217
Summary: This study aimed to assess the prevalence of severe heart failure, its associated cardiovascular outcome risk, and the treatment response to finerenone, a non-steroidal mineralocorticoid receptor antagonist. The F.I.N.E.A.R.T.S.-H.F. trial specifically focused on patients with severe heart failure across the full spectrum of left ventricular ejection fraction. The research seeks to clarify the role and efficacy of finerenone in a broad heart failure population. This investigation could broaden therapeutic options for severe heart failure, irrespective of left ventricular ejection fraction.
Article 3: Short- and mid-term effects of empagliflozin on sodium balance and fluid regulation in chronic heart failure.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41186108
Summary: This randomized, placebo-controlled trial investigated the effects of empagliflozin on fluid and sodium balance over a three-month period in patients with chronic heart failure. Seventy-four patients with New York Heart Association class I.I. to I.I.I. chronic heart failure and an ejection fraction of 49 percent or less were enrolled. The study aimed to determine the persistence of empagliflozin’s beneficial effects beyond the acute phase, where urinary glucose and sodium excretion are well-established. This research is crucial for optimizing long-term management strategies for chronic heart failure.
Article 4: Sex Disparities in Ischemic Heart Disease Mortality Across United States: The Southern Burden of Excess Body Weight and Diet.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41182171
Summary: This study analyzed sex disparities in ischemic heart disease mortality across all 50 states in the United States between 2011 and 2021. Researchers utilized Global Burden of Disease data to calculate sex-specific age-standardized ischemic heart disease mortality rates and prevalence rates. The analysis also involved determining mortality-to-prevalence ratios to compare outcomes across states. This research aims to pinpoint geographical variations in ischemic heart disease outcomes and their potential association with lifestyle factors, which could guide targeted public health interventions.
Article 5: Growth Trajectories in Ascending Thoracic Aortic Dilation: Classification and Implications for the Effectiveness of Real-World Imaging Surveillance.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41182163
Summary: This retrospective, single-center study characterized ascending aortic growth trajectories to better inform surveillance strategies for ascending aortic dilation. The research addressed the clinical challenge that Type A dissections often occur at non-surgical sizes despite serial imaging monitoring. Mid-ascending aortic diameters from patients who underwent two or more computed tomography angiography or magnetic resonance angiography examinations were analyzed. This study aims to provide a more refined understanding of aortic dilation progression, thereby optimizing real-world imaging surveillance and patient management.
Transcript
Today’s date is November 05, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Transgender persons receiving gender-affirming hormone therapy: risk of acute cardiovascular events in a Dutch cohort study. This study investigated the association between gender-affirming hormone therapy and cardiovascular event risk in transgender individuals compared to the general population. A key methodological advancement was the adjustment for socioeconomic status and lifestyle factors, which were not accounted for in previous research. This Dutch cohort study aims to provide a more accurate assessment of cardiovascular risk in this specific population. The research is critical for refining cardiovascular care guidelines and enhancing risk stratification for transgender persons receiving gender-affirming hormone therapy.
Article number two. Finerenone in patients with severe heart failure: The FINEARTS-HF trial. This study aimed to assess the prevalence of severe heart failure, its associated cardiovascular outcome risk, and the treatment response to finerenone, a non-steroidal mineralocorticoid receptor antagonist. The F.I.N.E.A.R.T.S.-H.F. trial specifically focused on patients with severe heart failure across the full spectrum of left ventricular ejection fraction. The research seeks to clarify the role and efficacy of finerenone in a broad heart failure population. This investigation could broaden therapeutic options for severe heart failure, irrespective of left ventricular ejection fraction.
Article number three. Short- and mid-term effects of empagliflozin on sodium balance and fluid regulation in chronic heart failure. This randomized, placebo-controlled trial investigated the effects of empagliflozin on fluid and sodium balance over a three-month period in patients with chronic heart failure. Seventy-four patients with New York Heart Association class I.I. to I.I.I. chronic heart failure and an ejection fraction of 49 percent or less were enrolled. The study aimed to determine the persistence of empagliflozin’s beneficial effects beyond the acute phase, where urinary glucose and sodium excretion are well-established. This research is crucial for optimizing long-term management strategies for chronic heart failure.
Article number four. Sex Disparities in Ischemic Heart Disease Mortality Across United States: The Southern Burden of Excess Body Weight and Diet. This study analyzed sex disparities in ischemic heart disease mortality across all 50 states in the United States between 2011 and 2021. Researchers utilized Global Burden of Disease data to calculate sex-specific age-standardized ischemic heart disease mortality rates and prevalence rates. The analysis also involved determining mortality-to-prevalence ratios to compare outcomes across states. This research aims to pinpoint geographical variations in ischemic heart disease outcomes and their potential association with lifestyle factors, which could guide targeted public health interventions.
Article number five. Growth Trajectories in Ascending Thoracic Aortic Dilation: Classification and Implications for the Effectiveness of Real-World Imaging Surveillance. This retrospective, single-center study characterized ascending aortic growth trajectories to better inform surveillance strategies for ascending aortic dilation. The research addressed the clinical challenge that Type A dissections often occur at non-surgical sizes despite serial imaging monitoring. Mid-ascending aortic diameters from patients who underwent two or more computed tomography angiography or magnetic resonance angiography examinations were analyzed. This study aims to provide a more refined understanding of aortic dilation progression, thereby optimizing real-world imaging surveillance and patient management.
Thank you for listening. Don’t forget to subscribe.
Keywords
gender-affirming hormone therapy, United States, left ventricular ejection fraction, clinical trial, public health, heart failure, lifestyle factors, empagliflozin, chronic heart failure, ischemic heart disease, computed tomography angiography, sex disparities, mortality rates, fluid regulation, growth trajectories, transgender health, cardiovascular risk, imaging surveillance, mineralocorticoid receptor antagonist, aortic dissection, ascending aortic dilation, finerenone, socioeconomic status, sodium balance, randomized controlled trial.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post Aortic Dilation Growth Patterns Reshape Surveillance 11/05/25 first appeared on Cardiology Today.
Article Links:
Article 1: Transgender persons receiving gender-affirming hormone therapy: risk of acute cardiovascular events in a Dutch cohort study. (European heart journal)
Article 2: Finerenone in patients with severe heart failure: The FINEARTS-HF trial. (European journal of heart failure)
Article 3: Short- and mid-term effects of empagliflozin on sodium balance and fluid regulation in chronic heart failure. (European journal of heart failure)
Article 4: Sex Disparities in Ischemic Heart Disease Mortality Across United States: The Southern Burden of Excess Body Weight and Diet. (Journal of the American Heart Association)
Article 5: Growth Trajectories in Ascending Thoracic Aortic Dilation: Classification and Implications for the Effectiveness of Real-World Imaging Surveillance. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/aortic-dilation-growth-patterns-reshape-surveillance-11-05-25/
Featured Articles
Article 1: Transgender persons receiving gender-affirming hormone therapy: risk of acute cardiovascular events in a Dutch cohort study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41187090
Summary: This study investigated the association between gender-affirming hormone therapy and cardiovascular event risk in transgender individuals compared to the general population. A key methodological advancement was the adjustment for socioeconomic status and lifestyle factors, which were not accounted for in previous research. This Dutch cohort study aims to provide a more accurate assessment of cardiovascular risk in this specific population. The research is critical for refining cardiovascular care guidelines and enhancing risk stratification for transgender persons receiving gender-affirming hormone therapy.
Article 2: Finerenone in patients with severe heart failure: The FINEARTS-HF trial.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41186217
Summary: This study aimed to assess the prevalence of severe heart failure, its associated cardiovascular outcome risk, and the treatment response to finerenone, a non-steroidal mineralocorticoid receptor antagonist. The F.I.N.E.A.R.T.S.-H.F. trial specifically focused on patients with severe heart failure across the full spectrum of left ventricular ejection fraction. The research seeks to clarify the role and efficacy of finerenone in a broad heart failure population. This investigation could broaden therapeutic options for severe heart failure, irrespective of left ventricular ejection fraction.
Article 3: Short- and mid-term effects of empagliflozin on sodium balance and fluid regulation in chronic heart failure.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41186108
Summary: This randomized, placebo-controlled trial investigated the effects of empagliflozin on fluid and sodium balance over a three-month period in patients with chronic heart failure. Seventy-four patients with New York Heart Association class I.I. to I.I.I. chronic heart failure and an ejection fraction of 49 percent or less were enrolled. The study aimed to determine the persistence of empagliflozin’s beneficial effects beyond the acute phase, where urinary glucose and sodium excretion are well-established. This research is crucial for optimizing long-term management strategies for chronic heart failure.
Article 4: Sex Disparities in Ischemic Heart Disease Mortality Across United States: The Southern Burden of Excess Body Weight and Diet.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41182171
Summary: This study analyzed sex disparities in ischemic heart disease mortality across all 50 states in the United States between 2011 and 2021. Researchers utilized Global Burden of Disease data to calculate sex-specific age-standardized ischemic heart disease mortality rates and prevalence rates. The analysis also involved determining mortality-to-prevalence ratios to compare outcomes across states. This research aims to pinpoint geographical variations in ischemic heart disease outcomes and their potential association with lifestyle factors, which could guide targeted public health interventions.
Article 5: Growth Trajectories in Ascending Thoracic Aortic Dilation: Classification and Implications for the Effectiveness of Real-World Imaging Surveillance.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41182163
Summary: This retrospective, single-center study characterized ascending aortic growth trajectories to better inform surveillance strategies for ascending aortic dilation. The research addressed the clinical challenge that Type A dissections often occur at non-surgical sizes despite serial imaging monitoring. Mid-ascending aortic diameters from patients who underwent two or more computed tomography angiography or magnetic resonance angiography examinations were analyzed. This study aims to provide a more refined understanding of aortic dilation progression, thereby optimizing real-world imaging surveillance and patient management.
Transcript
Today’s date is November 05, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Transgender persons receiving gender-affirming hormone therapy: risk of acute cardiovascular events in a Dutch cohort study. This study investigated the association between gender-affirming hormone therapy and cardiovascular event risk in transgender individuals compared to the general population. A key methodological advancement was the adjustment for socioeconomic status and lifestyle factors, which were not accounted for in previous research. This Dutch cohort study aims to provide a more accurate assessment of cardiovascular risk in this specific population. The research is critical for refining cardiovascular care guidelines and enhancing risk stratification for transgender persons receiving gender-affirming hormone therapy.
Article number two. Finerenone in patients with severe heart failure: The FINEARTS-HF trial. This study aimed to assess the prevalence of severe heart failure, its associated cardiovascular outcome risk, and the treatment response to finerenone, a non-steroidal mineralocorticoid receptor antagonist. The F.I.N.E.A.R.T.S.-H.F. trial specifically focused on patients with severe heart failure across the full spectrum of left ventricular ejection fraction. The research seeks to clarify the role and efficacy of finerenone in a broad heart failure population. This investigation could broaden therapeutic options for severe heart failure, irrespective of left ventricular ejection fraction.
Article number three. Short- and mid-term effects of empagliflozin on sodium balance and fluid regulation in chronic heart failure. This randomized, placebo-controlled trial investigated the effects of empagliflozin on fluid and sodium balance over a three-month period in patients with chronic heart failure. Seventy-four patients with New York Heart Association class I.I. to I.I.I. chronic heart failure and an ejection fraction of 49 percent or less were enrolled. The study aimed to determine the persistence of empagliflozin’s beneficial effects beyond the acute phase, where urinary glucose and sodium excretion are well-established. This research is crucial for optimizing long-term management strategies for chronic heart failure.
Article number four. Sex Disparities in Ischemic Heart Disease Mortality Across United States: The Southern Burden of Excess Body Weight and Diet. This study analyzed sex disparities in ischemic heart disease mortality across all 50 states in the United States between 2011 and 2021. Researchers utilized Global Burden of Disease data to calculate sex-specific age-standardized ischemic heart disease mortality rates and prevalence rates. The analysis also involved determining mortality-to-prevalence ratios to compare outcomes across states. This research aims to pinpoint geographical variations in ischemic heart disease outcomes and their potential association with lifestyle factors, which could guide targeted public health interventions.
Article number five. Growth Trajectories in Ascending Thoracic Aortic Dilation: Classification and Implications for the Effectiveness of Real-World Imaging Surveillance. This retrospective, single-center study characterized ascending aortic growth trajectories to better inform surveillance strategies for ascending aortic dilation. The research addressed the clinical challenge that Type A dissections often occur at non-surgical sizes despite serial imaging monitoring. Mid-ascending aortic diameters from patients who underwent two or more computed tomography angiography or magnetic resonance angiography examinations were analyzed. This study aims to provide a more refined understanding of aortic dilation progression, thereby optimizing real-world imaging surveillance and patient management.
Thank you for listening. Don’t forget to subscribe.
Keywords
gender-affirming hormone therapy, United States, left ventricular ejection fraction, clinical trial, public health, heart failure, lifestyle factors, empagliflozin, chronic heart failure, ischemic heart disease, computed tomography angiography, sex disparities, mortality rates, fluid regulation, growth trajectories, transgender health, cardiovascular risk, imaging surveillance, mineralocorticoid receptor antagonist, aortic dissection, ascending aortic dilation, finerenone, socioeconomic status, sodium balance, randomized controlled trial.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post Aortic Dilation Growth Patterns Reshape Surveillance 11/05/25 first appeared on Cardiology Today.
In God we trust